ZA201204628B - Immunogenic compositions - Google Patents

Immunogenic compositions

Info

Publication number
ZA201204628B
ZA201204628B ZA2012/04628A ZA201204628A ZA201204628B ZA 201204628 B ZA201204628 B ZA 201204628B ZA 2012/04628 A ZA2012/04628 A ZA 2012/04628A ZA 201204628 A ZA201204628 A ZA 201204628A ZA 201204628 B ZA201204628 B ZA 201204628B
Authority
ZA
South Africa
Prior art keywords
immunogenic compositions
immunogenic
compositions
Prior art date
Application number
ZA2012/04628A
Other languages
English (en)
Inventor
Scott Gallichan
Garry Morefield
Belma Ljutic
Marie-Danielle Salha
Kevin Harper
Martina Ochs Ochs
Fernando Ausar
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of ZA201204628B publication Critical patent/ZA201204628B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2012/04628A 2009-12-22 2012-06-21 Immunogenic compositions ZA201204628B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US32566010P 2010-04-19 2010-04-19
PCT/CA2010/001977 WO2011075823A1 (en) 2009-12-22 2010-12-20 Immunogenic compositions

Publications (1)

Publication Number Publication Date
ZA201204628B true ZA201204628B (en) 2013-02-27

Family

ID=44194860

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/04628A ZA201204628B (en) 2009-12-22 2012-06-21 Immunogenic compositions

Country Status (12)

Country Link
US (1) US20130183350A1 (enExample)
EP (1) EP2515938A4 (enExample)
JP (2) JP5894083B2 (enExample)
KR (1) KR20120107121A (enExample)
CN (1) CN102802664B (enExample)
AR (1) AR079712A1 (enExample)
AU (1) AU2010335970B2 (enExample)
BR (1) BR112012018343A2 (enExample)
CA (1) CA2783955A1 (enExample)
IL (2) IL220576B (enExample)
WO (1) WO2011075823A1 (enExample)
ZA (1) ZA201204628B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784447A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Adjuvanted immunogenic compositions and related methods
CA2819758A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CN104853768B (zh) * 2012-10-17 2019-04-19 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CA2894903A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
EP3116537A4 (en) * 2014-03-10 2017-09-13 Sanofi Pasteur Limited Immunogenic compositions
KR101688960B1 (ko) * 2014-06-11 2016-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물
JP2018502927A (ja) * 2015-01-27 2018-02-01 スリーエム イノベイティブ プロパティズ カンパニー マイクロニードルワクチンパッチ用ミョウバン含有コーティング製剤
GB2556002B (en) * 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT58804A (en) * 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
DK1140157T3 (da) * 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP1863529A1 (en) * 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2007285775B2 (en) * 2006-08-17 2011-03-03 Sanofi Pasteur Ltd. Immunogenic PcpA polypeptides and uses thereof
AU2008280799B2 (en) 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
AU2009208299B2 (en) * 2008-02-01 2015-01-22 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
BRPI0923649A2 (pt) * 2008-12-24 2016-01-19 Netherlands Vaccine Inst polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.

Also Published As

Publication number Publication date
AU2010335970B2 (en) 2016-11-03
CN102802664B (zh) 2017-04-05
IL242592A (en) 2017-10-31
BR112012018343A2 (pt) 2017-06-27
US20130183350A1 (en) 2013-07-18
AR079712A1 (es) 2012-02-15
KR20120107121A (ko) 2012-09-28
IL220576B (en) 2018-03-29
EP2515938A4 (en) 2013-08-28
JP2013515015A (ja) 2013-05-02
EP2515938A1 (en) 2012-10-31
WO2011075823A1 (en) 2011-06-30
AU2010335970A1 (en) 2012-07-05
CN102802664A (zh) 2012-11-28
JP2016104776A (ja) 2016-06-09
JP5894083B2 (ja) 2016-03-23
CA2783955A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
GB0913681D0 (en) Immunogenic composition
ZA201109176B (en) Homeglobin compositions
IL217949A0 (en) Pesticdal compositions
GB0906515D0 (en) Fungical compositions
GB201003924D0 (en) Immunogenic composition
ZA201106050B (en) Dye-polymers formulations
ZA201109312B (en) Compositions
PT2402032T (pt) Composição imunogénica
IL242592A (en) Immunogenic compounds
GB0910046D0 (en) Novel compositions
IL269369A (en) The vehicles are improved
ZA201107838B (en) Composition
GB0919210D0 (en) Formulations
IL214127A0 (en) Vaccine compositions
GB0910045D0 (en) Novel compositions
EP2252326A4 (en) VACCINE COMPOSITIONS
EP2640418A4 (en) IMMUNOGENIC COMPOSITIONS
GB0913680D0 (en) Immunogenic composition
IL220308A0 (en) Vaccine compositions
GB0905165D0 (en) Compositions
ZA201301908B (en) Immunogenic compositions
GB0908963D0 (en) Compositions
IL217390A0 (en) Formulations
GB0900943D0 (en) Vaccine compositions
GB0911458D0 (en) Compositions